Toggle Main Menu Toggle Search

Open Access padlockePrints

Ditropan XL

Lookup NU author(s): Professor Farhad Kamali

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Alza is developing both transdermal and oral (utilizing OROS technology) formulations of the established muscarinic antagonist, oxybutynin, for the treatment of urinary incontinence. The formulations are being developed to improve dosing and reduce side-effects associated with existing formulations of the drug. In December 1997, Alza filed an NDAfor its sustained-release, oncedaily oral formuktion as Ditropan XL 1273067]. This was approved in December 1998 1309867]. US market launch was in early February 1999 1312976]', and Merrill Lynch predicts 1999 revenues to reach $60 million 1300521,10951]. Alza intends to expand the Ditropan line, and plans to introduce a 15 mg tablet by mid-19991314879]. Crescendo has obtained a worldwide license 1309867]. A commercialization agreement for Europe has been made with Synthelabo 1309869]. The product will be filed in Europe during 1999 [312642]. Information on the drug can be found on the Internet at www.DitropanXL.com © Current Drugs Ltd.


Publication metadata

Author(s): ALZA Corporation, Kamali F

Publication type: Article

Publication status: Published

Journal: IDrugs

Year: 1999

Volume: 2

Issue: 4

Pages: 360-365

Print publication date: 01/01/1999

ISSN (print): 1369-7056

ISSN (electronic):


Actions

Find at Newcastle University icon    Link to this publication


Share